Short Name: IPRI
The International Prevention Research Institute (iPRI) is a research institute devoted to Global Public Health, where highly experienced Public Health Scientists, Epidemiologists, Statisticians and computational biologists work together. iPRI has unparalleled experience in epidemiological research and macro health planning with a record of delivering real health and economic value to a range of public and private sources including governments, universities, research institutes, non-governmental organisations and large multi-national concerns.
With the University of Strathclyde (UK), iPRI has created the “Strathclyde institute of Global Public Health at iPRI” in Lyon, France.
IPRI yearly organizes the National Cancer Institute Directors (NCID). The NCID is a unique dissemination event that attracts Cancer Institute leadership and key stakeholders across the cancer spectrum. iPRI, in collaboration with the World Prevention Alliance (WPA), places particular focus on the participation of scientists from lower resource countries
PH Area: i) Design of large scale PH plans (& PH impact assessment); ii) Public Health Sciences; iii) Science with and for the Society (a.k.a. “Science in Society”); iv) Dissemination and Communication
Computational Area: i) Computational Biology; ii) Epidemiology of Cancer and of Communicable and non-communicable diseases; iii) PK/PD modelling; iv) Medical computer Sciences; v) Statistics Facilities: iPRI employs 19 people on its permanent staff and has an international network of more than 50 senior research fellows. Since 2009, iPRI has published 472 papers. iPRI has a multidisciplinary team of senior researchers in global public heath, computational biology and statistics. Several senior researchers have been appointed to various universities in the world. iPRI provides all facilities for research (IT support, librarian, etc). iPRI has 2 PhD students and 7 junior researchers. The iPRI research premises are wholly independent from other consortium members.
Other European projects:
iPRI is beneficiary in several H2020 and FP 7 projects: ONCOTRACK (www.oncotrack.eu) (leader), ASSET (www.asset-scienceinsociety.eu), BBMRI-LPC, Eye-Light (www.i-pri.org/eye-light) (leader) and the ECNIS Network of Excellence
Role in the project:
IPRI provides valuable expertise in public health and health policy to the consortium. Furthermore, IPRI is key in international outreach and dissemination through the international National Cancer Institute Director network.
Prof. Peter Boyle
Prof. Peter Boyle, PhD, Male. H-index 90 about. Professor Boyle, IPRI President and Scientific Director of the Strathclyde Institute of Global Public Health, is an internationally well-known Global Public Health Scientist and cancer prevention advocate (European Code against Cancer, European Tobacco Products Directive, Globalisation of Cancer). He is a past Director of the WHO International Agency for Research on Cancer, is professor of Global Public Health at the Strathclyde University and honorary professor at several universities. He has published extensively with major contributions on lung, breast and prostate cancers as well as of cancer geostatistics. A number of prof Boyle’s researches had a major impact on international and national cancer prevention plans. Prof. Boyle has a strong experience in dissemination towards political and public health decision makers. He is Member of some major scientific Academies. In 2014, he received the ESMO Lifetime Achievement Award and in 2017 the Royal Medal of the Royal Society of Edinburgh. Peter Boyle has previously been a Member of the European Cancer Advisory Board and worked as the scientific advisor to the European Commission on the European Tobacco Contents Directive which was voted into law in 2002. He was also responsible for the revisions of the European Code Against Cancer.
Dr. Alberto d’Onofrio
Dr. Alberto d’Onofrio, PhD, Male. H-index: 38 about. Dr d’Onofrio, research Director at IPRI and Visiting Professor at Stractclyde University (Statistics and Mathematics Department), is a well-known computational biologist and Public Health Scientists. Previsously he has been a principal investigator in the Molecular Oncology Department of the European Institute of Oncology, Milan, Italy. He is a well-known scientist in computational oncology and epidemiology. He has been working for many years in EU and WHO large projects in the fields of: Science with and For the Society and pandemic preparedness (ASSET); Computational biology of cancer (ACGT, P-Medicine); Cancer prevention (2nd EU Code Against Cancer, WHO Atlas of Cancer Mortality in Europe).
Main publications and awards:
Boyle, Peter, et al. “European Code Against Cancer and scientific justification: third version (2003).” Annals of oncology 14.7 (2003): 973-1005
Gandini, S., Botteri, E., Iodice, S., Boniol, M., Lowenfels, A. B., Maisonneuve, P., & Boyle, P. (2008). Tobacco smoking and cancer: A meta‐analysis. International journal of cancer, 122(1), 155- 164.
Sullivan, Richard, et al. “Delivering affordable cancer care in high-income countries.” The lancet oncology 12.10 (2011): 933-980.
Ginsburg, Ophira, et al. “Changing global policy to deliver safe, equitable, and affordable care for women’s cancers.” The Lancet 389.10071 (2017): 871-880.
Puszynski, K., Gandolfi, A., & d’Onofrio, A. (2014). The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise. PLoS computational biology, 10(12), e1003991.
Wang, Zhen, et al. “Statistical physics of vaccination.” Physics Reports 664 (2016): 1-113.
Awards: Professor Boyle received in 2014 the ESMO Lifetime Achievement Award and in 2017 the Royal Medal of the Royal Society of Edinburgh.